ProQR Therapeutics N.V. Ordinary Shares PRQR
i
Market datapartial · fetched 2026-11-12T02:32:54.562Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:24:38.608213786Z
FundamentalsAlpha Vantage · unavailable
ProQR Therapeutics N.V. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 1.46 | 194.9% | 18.8% | |||
| 45Δ | 1.39 | 229.0% | 18.1% | 1.52 | 437.8% | 21.6% |
| 50Δ | 1.33 | 263.1% | 17.4% | 1.60 | 414.1% | 18.9% |
| 55Δ | 1.27 | 297.2% | 16.7% | 1.68 | 390.3% | 16.2% |
| 60Δ | 1.21 | 331.3% | 16.0% | 1.76 | 366.5% | 13.5% |
| 65Δ | 1.15 | 365.4% | 15.3% | 1.84 | 342.8% | 10.8% |
| 70Δ | 1.09 | 399.5% | 14.6% | 1.92 | 319.0% | 8.1% |
| 75Δ | 1.03 | 433.6% | 14.0% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 1.46
- IV
- 194.9%
- B/E move
- 18.8%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 1.39
- IV
- 229.0%
- B/E move
- 18.1%
- Pseudo strike
- 1.52
- IV
- 437.8%
- B/E move
- 21.6%
50Δ
- Pseudo strike
- 1.33
- IV
- 263.1%
- B/E move
- 17.4%
- Pseudo strike
- 1.60
- IV
- 414.1%
- B/E move
- 18.9%
55Δ
- Pseudo strike
- 1.27
- IV
- 297.2%
- B/E move
- 16.7%
- Pseudo strike
- 1.68
- IV
- 390.3%
- B/E move
- 16.2%
60Δ
- Pseudo strike
- 1.21
- IV
- 331.3%
- B/E move
- 16.0%
- Pseudo strike
- 1.76
- IV
- 366.5%
- B/E move
- 13.5%
65Δ
- Pseudo strike
- 1.15
- IV
- 365.4%
- B/E move
- 15.3%
- Pseudo strike
- 1.84
- IV
- 342.8%
- B/E move
- 10.8%
70Δ
- Pseudo strike
- 1.09
- IV
- 399.5%
- B/E move
- 14.6%
- Pseudo strike
- 1.92
- IV
- 319.0%
- B/E move
- 8.1%
75Δ
- Pseudo strike
- 1.03
- IV
- 433.6%
- B/E move
- 14.0%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 216.53% | |
| 219.62% | |
| 216.28% | |
| 215.94% | |
| 219.28% | |
| 213.91% | |
| 252.25% | |
| 232.98% | |
| 230.44% |
Biotechnology
PRTA
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The…
More →PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is…
More →PTGX
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is…
More →PVLA
Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from specific gene mutations.…
More →PYPD
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address…
More →PYXS
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating…
More →